A phase 1a/b study of RLBN1127 for treatment of NASH
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2018
Price : $35 *
At a glance
- Drugs RLBN-1127 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 03 Oct 2018 New trial record
- 02 Oct 2018 According to an Acquist Therapeutics media release, data from this study will be presented at the annual meeting of the American College of Rheumatology (ACR) (Oct 2018).
- 25 Sep 2018 According to an Acquist Therapeutics media release, update scientific findings and clinical development plans for its drug candidates in two diseases, nonalcoholic steatohepatitis (NASH) and gout will be present at the BIO Investor Forum (Oct 2018) .